OVERVIEW

OncoPep is developing PVX-410, the first cancer vaccine designed to stop the progression of myeloma from the smoldering phase to active disease.


OncoPep is dedicated to developing transformative targeted immuno-therapeutics to prevent the progression of cancer, restore quality of life among patients and extend survival rates. Through targeting multiple tumor-associated antigens through a vaccine comprised of four peptides, OncoPep’s proprietary technology is primed to be used in combination with agents that modulates the patient’s immune response. Our core technology is founded on discoveries in a multi-peptide approach to cancer vaccines by Dr. Kenneth Anderson, M.D., a world renowned leader in cancer treatment, at the Dana Farber Cancer Institute.  

Our initial focus is on smoldering multiple myeloma (SMM), a potential $400 million market with no approved therapeutic solution. In the United States, there is an estimated 80,000 cases per year and nearly 20,000 of these cases progress to multiple myeloma (MM). MM is the second most common blood cancer, affecting plasma cells, that has no cure.

OncoPep’s lead program, PVX-410, is a multi-peptide therapeutic cancer vaccine for use in treating smoldering multiple myeloma. PVX-410 is designed to be used in combination with agents that augment or modulates the patient’s immune response to the vaccine. PVX-410 was granted orphan drug designation from the U.S. Food and Drug Administration in 2013.

By addressing smoldering multiple myeloma, the precursor disease to multiple myeloma, OncoPep has the opportunity to drastically alter the rate of cancer progression in patients diagnosed with SMM or